Suchergebnisse - "Skin malignancy"

PubPharm (155)

1

In Vitro Modeling of Recurrent Dermatofibrosarcoma Protuberans : Assessment of 5-Aminolevulinic Acid Photodynamic Therapy Efficacy

enthalten in: Photodiagnosis and photodynamic therapy | 2024

von Jiang, H. | He, K. | Tan, J. | +7

2

How could we help to diagnose an atypical eccrine porocarcinoma?

enthalten in: Asian journal of surgery | 2024

von Yang, L. | Lai, M. | You, F. | +1

3

A meta-analysis of melanoma risk in idiopathic inflammatory myopathy patients

enthalten in: Zeitschrift fur Rheumatologie | 2024

von Luo, R. | Xia, D. | Yu, S.

4

Integrated Whole Exome and Transcriptome Sequencing in Cholesterol Metabolism in Melanoma: Systematic Review

in: Sudan Journal of Medical Sciences | 2024

von Mohammed Mahmoud Nour Eldin | Wesam Ahmed Nasif | Amr Ahmed Amin | +2

5

PLASTIC SURGERY OF WOUND DEFECTS WITH FREE GRAFTS AFTER MALIGNANT SKIN TUMORS EXCISION : A PILOT STUDY

enthalten in: Experimental oncology | 2023

von Korovin, S. | Dedkov, S. | Ostafiichuk, V. | +1

6

The incidence and cost implications of surgical site infection following lymph node surgery for skin malignancy

enthalten in: Journal of plastic, reconstructive & aesthetic surgery : JPRAS | 2023

von McMillan, A. | Ho, N. | Izard, C. | +2

7

Merkel Cell Carcinoma in an Elderly Male With Extensive Local Disease

enthalten in: Cureus | 2023

von Colef, R. | Kiran, N. | Mescallado, L. | +2

8

A PHASE IV, POSTMARKETING, OPEN-LABEL,EXTENSION (ROLLOVER) STUDY OFVEMURAFENIB IN PATIENTS WITH BRAFV600MUTATION−POSITIVE MALIGNANCIESPREVIOUSLY ENROLLED IN AN ANTECEDENTVEMURAFENIB PROTOCOL : A PHASE IV, POSTMARKETING, OPEN-LABEL,EXTENSION (ROLLOVER) STUDY OFVEMURAFENIB IN PATIENTS WITH BRAFV600MUTATION−POSITIVE MALIGNANCIESPREVIOUSLY ENROLLED IN AN ANTECEDENTVEMURAFENIB PROTOCOL

enthalten in: WHO International Clinical Trials Registry Platform | 2023

9

AN OPEN LABEL, PHASE I STUDY TOEVALUATE THE IMPACT OF SEVERE HEPATICIMPAIRMENT ON THE PHARMACOKINETICSAND SAFETY OF VEMURAFENIB IN BRAFV600MUTATION POSITIVE CANCER PATIENTS : AN OPEN LABEL, PHASE I STUDY TOEVALUATE THE IMPACT OF SEVERE HEPATICIMPAIRMENT ON THE PHARMACOKINETICSAND SAFETY OF VEMURAFENIB IN BRAFV600MUTATION POSITIVE CANCER PATIENTS

enthalten in: WHO International Clinical Trials Registry Platform | 2023

10

OPEN, MULTI-CENTER PHASE II TRIAL OF EXTENDED OR FOLLOW-UP TREATMENT WITH IPILIMUMAB (MDX-010) ADMINISTERED AS MONOTHERAPY TO PATIENTS PREVIOUSLY IN PROTOCOLS WITH IPILIMUMAB (MDX-010) : OPEN, MULTI-CENTER PHASE II TRIAL OF EXTENDED OR FOLLOW-UP TREATMENT WITH IPILIMUMAB (MDX-010) ADMINISTERED AS MONOTHERAPY TO PATIENTS PREVIOUSLY IN PROTOCOLS WITH IPILIMUMAB (MDX-010)

enthalten in: WHO International Clinical Trials Registry Platform | 2023

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]